Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease
Objective: To develop novel, small molecular weight compounds, that can interfere with the aggregation process of alpha-synuclein (aSyn), as disease modifying agents. Background: The aggregation…Alpha-synuclein aggregates of cardiac sympathetic nerves in synucleinopathies and in neurologically unimpaired subjects. Correlation with sympathetic denervation
Objective: To study the cardiac sympathetic innervation and its relationship with the incidence of alpha-synuclein deposits in heart tissue of synucleinopathies and asymptomatic control patients.…Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein
Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…Toward a new biomarker on Parkinson’s disease: Study of alpha synuclein on upper enteric system by endoscopy
Objective: The aim of our study was to investigate the alpha synuclein deposition at the enteric nerve system on patient with Parkinson's disease and provide…Alpha-synuclein in gastric and colonic mucosa in Parkinson’s disease: Limited role as a biomarker
Objective: We aimed to investigate the utility of alpha-synuclein (α-SYN) immunoreactivity from gastric and colonic mucosal tissues obtained by routine endoscopy to detect Parkinson's disease…Protein levels of SV2A and VGLUT1 in brain tissue from patients with Parkinson’s disease, dementia with Lewy bodies and Alzheimer’s disease
Objective: The objective of this study was to investigate whether SV2A and/or VGLUT1 are suitable as markers for synaptic degeneration in neurodegenerative disorders and could…Novel PET Tracers of alpha-synuclein for the diagnosis of Parkinson’s disease
Objective: The aim of our project is to develop small molecular weight compounds (Morphomers™) which bind selectively to alpha-synuclein (aSyn) aggregates, in order to generate…Targeted over-expression with AAV-mediated human α-synuclein in a rat model of Parkinson’s disease – Validation of novel fine motor functional effects
Objective: Targeted over-expression of human α-synuclein using viral-vector mediated gene delivery into the substantia nigra of rats and non-human primates has been reported to lead…Correlation between neuro-behavioral symptoms, cognition and gait in patients with dementia with Lewy bodies (DLB)
Objective: To determine the prevalence of neurobehavioral disturbances and their relationship to gait and cognitive impairment in DLB. Background: The recent literature has conceptualized that…
- « Previous Page
- 1
- …
- 6
- 7
- 8